Welcome to SEQ Services, your dedicated partner in empowering the development of orphan medicinal products tailored for rare medical conditions. Our specialized support ensures a seamless process from orphan designation to compelling case construction.
Orphan Medicinal Product Development: SEQ offers specialized services for the development of orphan medicinal products targeting rare medical conditions.
Navigating Orphan Designation: Our expertise aids in navigating the orphan designation process through the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP).
Comprehensive Assistance: SEQ provides comprehensive assistance, including collecting prevalence data, researching authorized products, and reviewing evidence for significant benefit.
Maximum 90-Day Evaluation: The orphan designation process ensures a swift 90-day evaluation period for applications.
Building the Case for Medical Plausibility: SEQ assists in building a compelling case for medical plausibility to support orphan drug development.
Explore how SEQ’s services can drive your orphan drug development. Contact us at enquiries@nerin.co.im for detailed support.
